Loading page
Loading page
Loading substance route
Allylescaline is not habit-forming, and the desire to use it can actually decrease with use. It is most often self-regulating.
No evidence of physical dependence. The substance is described as not habit-forming.
The exact toxic dose is unknown. Allylescaline is a research chemical with very little history of human usage and its toxicity has not been studied in any scientific context.
Allylescaline was first documented in the scientific literature by Czech chemist Otakar Leminger in 1972. The compound received broader attention when American chemist Alexander Shulgin synthesized and characterized its psychoactive effects, publishing his findings in the 1991 book PiHKAL: A…
Controlled under the Narcotics Act (Betäubungsmittelgesetz) Schedule I since February 1, 1997, listed as '4-Allyloxy-3,5-dimethoxy-phenethylazan'. Manufacturing, possession, import, export, purchase, sale, procurement, and dispensation without a license are prohibited.
Classified as an illegal substance since January 2016.
Production, supply, and import prohibited under the Psychoactive Substances Act 2016, which came into effect on May 26, 2016.
Designated as a controlled substance effective March 25, 2015.
Specifically named and controlled under Verzeichnis E of Swiss narcotics legislation.
Not directly scheduled under the Controlled Substances Act. However, due to structural similarities with mescaline, sale for human consumption or use for illicit purposes could potentially be prosecuted under the Federal Analogue Act.
9 sources cited
